Latest Period
Q1 2026
Security Snapshot
Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) Institutional Ownership
CUSIP: 03771D102
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
6
Shares (Excl. Options)
448,756
Price
$1.79
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- APUS on NYSE
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 448,756
- Total 13F value
- $802,954
- Portfolio coverage rank
- 0%
- Share change
- -7,920
- Value change
- -$10,103
- Number of holders
- 6
- Shares outstanding
- 12,584,892
- SEC-reported price per share
- $1.30
- Insider filing price
- $1.30
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock is tracked under CUSIP 03771D102.
- 6 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 7 to 6 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $648,947 to $802,954.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 6 institutions filings for Q1 2026.
Security key
03771D102
Latest holder period
Q1 2026
13F holders
6
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
APUS full holder history
Apimeds Pharmaceuticals US, Inc. SEC filings
Apimeds Pharmaceuticals US, Inc. company facts
Apimeds Pharmaceuticals US, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03771D102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
APUS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Inscobee Inc. | 34% | 0% | $7,722,861 | 4,316,618 | 0% | Apimeds Inc. | 07 May 2026 | |
| Ayrton Capital LLC | 10% | $2,612,429 | 1,397,021 | Ayrton Capital LLC | 31 Dec 2025 |
As of 31 Mar 2026, 6 institutional investors reported holding 448,756 shares of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS). This represents 3.6% of the company’s total 12,584,892 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Latest
Q1 2026
Rows shown
1-4 of 4